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Summary 
 
A two-step culture system was used to investigate the role of chondroitin 
sulfate(CS) B , which is mitogenic to B cells, in differentiation of B cells. Mouse spleen 
B cells were incubated for 3 days with CSB in the presence of interleukin (IL)-4 and 
IL-5. After washing, the cells were replated at 105 viable cells/well and recultured 
without CSB in the presence of IL-4 and IL-5. CSB dose-dependently increased IgM 
production, the greatest enhancement being 450%. Dextran sulfate had a similar effect, 
whereas other glycosaminoglycans, CSA, CSC, heparin and hyaluronic acid, were 
marginally effective. Treatment of B cells with CSB resulted in increases in the number 
of IgM-secreting cells and numbers of CD138-positive cells and CD45R/B220-negative 
cells. CSB-induced IgM production was inhibited by the protein kinase C (PKC) 
inhibitor GF109203X but not by the phosphatidylinositol 3-kinase (PI3K) inhibitor 
wortmannin. These results demonstrated that CSB promoted differentiation of B cells in 
the presence of IL-4 and IL-5 and suggested that PKC but not PI3K is crucial for 
CSB-induced IgM production.  
 
 
Keywords: Chondroitin sulfate B (CSB); Murine B cells; IgM; Differentiation; CD138; 
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1. Introduction      
 
Chondroitin sulfate is a sulfated glycosaminoglycan composed of a long 
unbranched polysaccharide chain with a repeating disaccharide structure of 
N-acetylgalactosamine and glucuronic acid [1,2]. Most of N-acetylgalactosamine 
residues are sulfated, particularly in the 4 or 6 position, making chondroitin sulfate a 
strongly charged polyanion with a high water-draining power. Chondroitin 4-sulfate and 
chondroitin 6-sulfate are often called chondroitin sulfate A (CSA) and chondroitin 
sulfate C (CSC), respectively. Chondroitin sulfate B (CSB), also known as dermatan 
sulfate, is a stereoisomeric form of chondroitin sulfate with varying proportions of 
iduronic acid in place of glucuronic acid [1-3]. O-Sulfo groups are found on the 4- or 
6-position of N-acetylgalactosamine residues or the 2-position of iduronic acid residues 
of CSB. CSB is often found attached to a protein core, resulting in a macromolecule 
called a proteoglycan. CSB proteoglycans localize on cell surfaces and in the 
extracellular matrix and exist excessively in fibrous connective tissues such as skin, 
tendon, skeletal muscle, blood vessels, bone and cartilage. CSB has been the topic of 
limited studies in comparison to the more commonly studied glycosaminoglycans such 
as heparan sulfate, heparin and hyaluronic acid, but recent studies have shown that CSB 
has intriguing functions in central nervous system development, wound repair, infection, 
growth factor signaling, morphogenesis and cell division, in addition to its conventional 
structural roles [3-5].    
CSB has also been implicated in the pathogenesis of rheumatoid arthritis, a 
chronic, systemic and inflammatory autoimmune disease of connective tissue. Several 
changes in glycosaminoglycan expression in synovial tissue and cartilage of rheumatoid 
arthritis and osteoarthritis patients have been described. In synovial tissue of 
rheumatoid arthritis patients, CSB has been shown to be the primary molecular species 
of chondroitin sulfate in inflammatory areas compared with fibrotic areas where CSA/C 
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expression dominates [6]. CSB is the dominant glycosaminoglycan in proteoglycans 
secreted by synovial cells [7]. Basic activity of the disease and proliferation of the 
synovial cells correlate with an increased percentage of CSB of the total 
glycosaminoglycan content in the synovium [8]. Furhtermore, rheumatoid arthritis 
chondrocytes are known to synthesize an increased proportion of proteoglycans, 
enriched in CSB [9]. A growing number of pathogens, including viruses, parasites and 
bacteria, have been shown to use cell-surface chondroitin sulfate and CSB, in addition 
to heparan sulfate, for their attachment to host cells and tissues [3,10]. CSB as well as 
hyaluronic acid has been shown to inhibit an activity of antithrombin, a plasma inhibitor 
of thrombin [11]. Thrombin plays a key role in enhancing synovial thickness and 
inflammation during the pathogenesis of rheumatoid arthritis through its cleavage of 
fibrinogen to form a fibrin clot and its mitogenic effect on synovial cells [12,13]. 
Moreover, in mice, injection of glycosaminoglycans such as CSB, CSA, CSC, and 
hyaluronic acid has been shown to induce the onset of arthritis, tendosynovitis and 
dermatitis [14]. 
Prompted by the growing evidence of involvement of CSB in the pathogenesis of 
rheumatoid arthritis, we initiated an examination of the effects of CSB on functions of 
immune cells infiltrating inflammatory areas. We have recently found that CSB but not 
CSA or CSC stimulated the polyclonal proliferation of murine B cells as markedly as 
did anti-IgM antibody and more markedly than did dextran sulfate [15]. Our data 
suggested that phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) are 
crucial but that extracellular signal-regulated kinase (ERK) is less important for the 
mitogenc activity of CSB, the signaling pathways of which may be at least partly 
distinct from those of anti-IgM and lipopolysaccharide (LPS). Rachmilewitz and 
Tykocinski reported that CSB stimulated the proliferation of B cells in human 
peripheral blood mononuclear cells in a monocyte-dependent manner: on depletion of 
monocytes by adherence to tissue culture flasks, the residual nonadherent cells no 
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longer proliferated when exposed to CSB [16]. Murine splenic B cells, however, 
responded to CSB independently of adherent cells [15]. Inflammation, infection or 
physical damage can lead to the release of soluble CSB via degradation of the 
extracellular matrix in various fibrous connective tissues. Increased soluble CSB may 
cause polyclonal activation of B cells that could play a role at sites of inflammation and 
participate in the regulation of autoimmune response. To the best of our knowledge, 
however, no studies on CSB-induced differentiation of B cells have been reported to 
date. Since some stimuli which induce proliferation of B cells do not promote or rather 
inhibit B-cell differentiation [17,18], this study was undertaken to examine the effect of 
CSB on polyclonal antibody production in B cells. Our data indicated that CSB 
promoted polyclonal differentiation of B cells to antibody-producing cells in the 
presence of IL-4 and IL-5, and we also obtained evidence that PKC but not PI3K is 
crucial for CSB-induced IgM production.  
 
2. Materials and methods 
 
2.1. Mice   
 
Female BALB/c mice were purchased from Charles River Japan (Yokohama, 
Japan). They were maintained under specific pathogen-free conditions in the animal 
facility of Okayama University and used between 8 and 12 weeks of age. 
 
2.2. Reagents and antibodies   
 
CSB sodium salt (porcine intestinal mucosa), heparin sodium salt (porcine 
intestinal mucosa), hyaluronic acid (bovine vitreous humor), dextran sulfate sodium salt, 
LPS from Escherichia coli 055:B5, and propidium iodide were obtained from Sigma 
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Chemical Co. (St. Louis, MO). CSB sodium salt (porcine intestinal mucosa) was also 
purchased from Celsus Laboratories (Cincinnati, OH) and used for some experiments. 
CSA sodium salt (whale cartilage) and CSC sodium salt (shark cartilage) were obtained 
from Nacalai Tesque (Kyoto, Japan). Recombinant mouse IL-4 and IL-5 were 
purchased from R&D Systems (Minneapolis, MN). GF109203X (Gö6850) and 
PD98059 were obtained from Calbiochem (La Jolla, CA). Wortmannin was purchased 
from Wako Pure Chemical Industries (Osaka, Japan). Purified mouse IgM, goat 
anti-mouse IgM antibody, and horseradish peroxidase-conjugated goat anti-mouse IgM 
antibody were obtained from Zymed Laboratories Inc (San Francisco, CA), Organon 
Teknika Corporation (Durham, NC), and Kirkegaad & Perry Laboratories (Gaithersburg, 
MD), respectively. Fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse 
CD45R/B220, phycoerythrin (PE)-conjugated rat anti-mouse CD138 (syndecan-1), 
FITC-conjugated hamster anti-mouse CD3 ε chain, anti-mouse CD16/CD32, 
anti-mouse IL-4, and biotinylated anti-mouse IL-4 monoclonal antibodies (mAbs) were 
purchased from BD Biosciences Pharmingen (San Jose, CA). Anti-mouse TNF-α 
antibody, biotinylated anti-mouse TNF-α antibody, anti-mouse IL-12 mAb, and 
biotinylated anti-mouse IL-12 antibody were obtained from R&D Systems 
(Minneapolis, MN). [6-3H]Thymidine was obtained from GE Healthcare Bio-Sciences 
(Little Chalfont, UK). 
  
2.3. Preparation of enriched B cells   
 
Murine spleen resting conventional (CD5−) B cells were enriched by negative 
selection using a mouse B lymphocyte enrichment set (BD Biosciences Pharmingen) as 
decribed previously [15]. Briefly, murine spleen cells depleted of erythrocytes by lysis 
of erythrocytes with ammonium chloride were suspended in Dulbecco’s minimum 
essential medium supplemented with 4 mM L-glutamine, 100 U/ml penicillin and 100 
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μg/ml streptomycin and incubated on plastic dishes for 90 min at 37 °C. The 
nonadherent cells were then collected, suspended in the same medium, and incubated on 
ice for 60 min with biotin-conjugated anti-mouse CD4, CD43 and TER-119/erythroid 
cell mAbs. The cells bearing the biotinylated antibodies were bound to BD IMag 
streptavidin particles, and negative selection was then performed on a BD IMagnet 
according to the manufacturer’s protocol to enrich the unlabeled B cells. The purity of 
recovered viable B cells was more than 97% when the cells were stained with 
FITC-conjugated anti-mouse CD45R/B220 mAb and propidium iodide after 
preincubation of the cells with anti-mouse CD16/CD32 mAb and analyzed by a flow 
cytometer (Epics XL, Beckman Coulter, Miami, FL). More than 95% cells in the 
enriched B cell preparations were small, resting B cells as judged by the cell size 
(forward scatter) in flow cytometry. 
 
  
2.4. Antibody response of enriched B cells   
 
Enriched B cells were first incubated with or without CSB in the basal culture 
medium (RPMI 1640 medium, supplemented with 10% heat-inactivated fetal calf serum, 
2 mM L-glutamine, 100 U/ml of penicillin G and 100 μg/ml of streptomycin) in the 
presence of 50 μM 2-mercaptoethanol, IL-4 (200 U/ml) and IL-5 (150 U/ml) for 3 days 
in round-bottom 96-well plates (2.5 × 105 cells/200 μl/well) at 37 °C in an atmosphere 
containing 5% CO2. The cells were washed twice with the basal culture medium to 
remove CSB and then recultured without CSB in the basal culture medium containing 
50 μM 2-mercaptoethanol, IL-4 (200 U/ml) and IL-5 (150 U/ml) for the indicated days 
in triplicate in round-bottom 96-well plates at a density of 1 × 105 cells/200 μl/well. The 
culture supernatant was then collected and was frozen at −30˚C for an IgM 
enzyme-linked immunosorbent assay (ELISA). The IgM levels were assayed by a 
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sandwich ELISA as described previously [19]. The number of viable cells was 
determined by a Trypan Blue dye-exclusion test. 
 
2.5. Enzyme-linked immunospot (ELISPOT) assay for detection of polyclonal 
IgM-secreting cells   
 
Detection of IgM-secreting cells was carried out as decribed by Sedgwick and 
Holt [20] and by Hodgkin et al. [21]. Briefly, each well of 96-well microtiter plates was 
coated with 50 μl of goat anti-mouse IgM antibody (10 μg/ml) by being incubated 
overnight at 4 ˚C and then washed three times with phosphate-buffered saline (PBS) 
containing 0.05% Tween-20. The plates were blocked with 200 μl of 1% bovine serum 
albumin in PBS for 2 h at room temperature and washed. To those plates, enriched B 
cells, which had been incubated with or without CSB for 2.5 days in the reculture 
period and washed with and suspended in the basal culture medium, were added (2.5 × 
103 cells/200 μl/well) in triplicate and incubated for 2 h at 37 °C. After being washed 
three times with PBS containing 0.05% Tween-20, the plates was incubated with 50 μl 
of horseradish peroxidase-conjugated goat anti-mouse IgM antibody (0.2 μg/ml) for 1 h 
at room temperature. After washing, 100 μl of substrate solution consisting of 50 mM 
sodium phosphate buffer (pH 7.0), 1% agarose, 2 mg/ml of diaminobenzidine, 0.0018% 
H2O2, 0.0018% NiCl2, and 0.0018% CoCl2 was added. The plates were incubated 
overnight at 37 °C in the dark, and the number of spot-forming cells was counted under 
a stereomicroscope. The data are expressed as the number of spot-forming cells per 105 
viable cells. 
  
2.6. Flow cytometric analysis of cell surface antigen expression   
 
Enriched B cells were incubated with or without CSB in the basal culture medium 
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containing 50 μM 2-mercaptoethanol, IL-4 (200 U/ml) and IL-5 (150 U/ml) for 3 days 
in 24-well plates (1.25 × 106 cells/1 ml/well). The cells were washed twice with the 
basal culture medium to remove CSB and then recultured without CSB in the basal 
culture medium containing 50 μM 2-mercaptoethanol, IL-4 (200 U/ml) and IL-5 (150 
U/ml) for 2.5 days in 24-well plates at a density of 5 × 105 cells/1 ml/well. The cells 
were then pooled and washed with and suspended in PBS containing 0.5% bovine 
serum albumin and 0.1% sodium azide (~ 1 × 106 cells/100 μl). The cells were 
incubated with anti-mouse CD16/CD32 mAb (10 μg/ml) for 5 min on ice to block 
Fc-mediated binding of antibodies to Fcγ receptor of cells and stained with 
FITC-conjugated anti-mouse CD45R/B220 mAb (10 μg/ml) or PE-conjugated rat 
anti-mouse CD138 mAb (4 μg/ml) for 30 min on ice. After being washed with and 
suspended in PBS containing 0.5% bovine serum albumin and 0.1% sodium azide, the 
cells were stained with propidium iodide (2 μg/ml), and expression of CD45R/B220 and 
CD138 on viable cells was analyzed by a flow cytometer (Epics XL, Beckman Coulter). 
  
2.7. Determination of DNA synthesis   
 
Enriched B cells (2.5 × 105/200 μl/well) were incubated with or without CSB or 
LPS in the basal culture medium containing 50 μM 2-mercaptoethanol, IL-4 (200 U/ml) 
and IL-5 (150 U/ml) for 45 h in triplicate in round-bottom 96-well plates. The cells 
were then pulse-labeled with [3H]thymidine (0.5 μCi/well, 2.5 Ci/mmol) for 3 h and 
harvested on glass fiber filters using a cell harvester as described previously [15]. The 
amount of [3H]thymidine incorporated was measured in a liquid scintillation counter. 
  
2.8. Determination of cytokine production   
 
Enriched B cells (2.5 × 105/200 μl/well) were incubated with or without CSB (6.3, 
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25, 100 μg/ml) or LPS (10 μg/ml) in the basal culture medium containing 50 μM 
2-mercaptoethanol for 1, 3 and 24 h. Levels of IL-4, IL-12 and TNF-α in cultured 
supernatants were measured by an ELISA. 
 
2.9. Data analysis   
 
Results are expressed as means and S.E.M. of three or four independent 
experiments. Data in two groups were analyzed by Student’s t-test. Multiple 
comparison of the data was done by Dunnett’s t-test or Dunnett’s T3-test. P values less 
than 5% were regarded as significant. 
 
3. Results 
 
3.1. The mitogenic effect of CSB on IL-4- and IL-5-stimulated B cells 
 
We have recently reported that CSB alone markedly stimulated proliferation of 
murine B cells in a basal culture medium [15]. The mitogenic effect of CSB on IL-4- 
and IL-5-stimulated B cells was examined. B cells, more than 95% cells of which were 
small, resting B cells, were incubated with or without varying doses of CSB in the 
presence of IL-4 and IL-5 for 45 h and pulse-labeled with [3H]thymidine for the next 3 
h. CSB stimulated DNA synthesis of B cells, and its dose-response curve was nearly 
linear up to 100 μg/ml (Fig. 1A). The number of viable cells in 72-h culture was 
dose-dependently increased by CSB, being a 50% increase over the control at 100 
μg/ml of CSB (Fig. 1B).  
 
3.2. Augmentation of IgM production in B cells by CSB and effects of other 
glycosaminoglycans 
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 Those cells stimulated with or without varying doses of CSB for 72 h as 
described above were then washed and recultured without CSB in the presence of IL-4 
and IL-5 for 4 days at an initial density of 1 × 105 cells/well. IgM produced was 
determined by an ELISA, and the results are shown in Fig. 2A. CSB dose-dependently 
increased IgM production, and its stimulatory effect reached a plateau at 6.3 μg/ml with 
maximal enhancement of 450%. The maximal effect of CSB was comparable to that of 
0.1 μg/ml of LPS (Fig. 2A). Since CSB was omitted during the reculture period, the 
viable cell density in the treated cultures did not significantly differ from that of the 
control cultures at the end of the reculture period (Fig. 2B). CSB obtained from Celsus 
Laboratories was as effective as CSB from Sigma Chemical Company (data not shown). 
IgG production was also markedly increased by CSB, although the levels of IgG were 
less than one fourth of IgM levels in the same culture at any doses of CSB (data not 
shown). Figure 2C shows a time course for CSB-induced increase in IgM production as 
well as LPS-induced increase. IgM levels in the culture supernatant of B cells treated 
with 6.25 μg/ml of CSB lineally increased with incubation time in a manner similar to 
that in cultures treated with 0.1 μg/ml of LPS. The stimulating effect of LPS (0.1 μg/ml) 
but not that of CSB was potently inhibited by polymyxin B (Fig. 2D). The effects of 
other glycosaminoglycans and dextran sulfate on IgM production in B cells are shown 
in Fig. 3. Dextran sulfate was as effective as CSB, but CSA, CSC, heparin, and 
hyaluronic acid were marginally effective or ineffective.  
 
3.3. CSB-induced differentiation of B cells 
 
The number of antibody-secreting cells in cultures treated with or without CSB 
for 2.5 days in the reculture period was determined by the ELISPOT assay, and the 
results were expressed as the number of spots per 105 viable cells. Treatment with 6.3, 
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25, and 100 μg/ml of CSB in the presenc of IL-4 and IL-5 resulted in a more than 400% 
increase in the number of IgM-secreting cells, similar to the effect of 0.1 μg/ml of LPS 
(Fig. 4A). The number of antibody-secreting cells in cultures incubated without IL-4 
and IL-5 was also significantly enhanced by CSB, although the absolute values were 
much lower than those in B cells incubated with IL-4 and IL-5 (Fig. 4B). B cells 
activated with CSB in the absence of IL-4 and IL-5 produced an increased amout of 
IL-12 but not IL-4 and, in contrast to B cells stimulated with LPS, TNF-α (data not 
shown). It is known that differentiation of naive B cells to plasma cells is accompanied 
by an increase in CD138 expression and by a decrease in CD45R/B220 expression 
[22,23]. B cells treated with or without CSB or LPS for 2.5 days in the second culture 
were subjected to analyses of expression of both cell-surface antigens by a flow 
cytometer. Both CSB and LPS significantly increased the percent of CD138-positive 
cells and the percent of CD45R/B220-negative cells (Fig. 5A−D).    
 
3.4. Requirement of PKC but not PI3K in CSB-induced IgM production 
 
We have recently shown that CSB caused translocation of PKC isoform β from 
cytosol to membrane fractions and increased phosphorylation of Akt but not 
phosphorylation of ERK of B cells and that PI3K and PKC are crucial but that ERK is 
less important for the B cell mitogenc activity of CSB [15]. In order to elucidate the role 
of those signaling pathways in CSB-induced differentiation of B cells, we conducted 
experiments using pharmacological inhibitors, and the results are shown in Fig. 6. 
When the inhibitors were included in the first culture period only, CSB-induced IgM 
production was potently inhibited by the PKC inhibitor GF109203X (1 μM) but not by 
the PI3K inhibitor wortmannin (100 nM) (Fig. 6A). In contrast, the mitogen-activated 
protein/ERK kinase (MEK) inhibitor PD98059 (12.5 μM) significantly enhanced IgM 
production promoted by CSB. On the other hand, LPS-induced IgM production was 
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partially inhibited by GF109203X but not by either wortmannin or PD98059. Similar 
results were obtained when each inhibitor was added to cultures during both the first 
culture and reculture periods (Fig. 6C), but none of the three inhibitors had any effect 
when they were included during the reculture period only (Fig. 6B).   
 
4. Discussion 
 
The results presented in this paper demonstrated that CSB markedly induced 
polyclonal differentiation of B cells to antibody-producing cells in the presence of IL-4 
and IL-5. Since polymyxin B had no influence on IgM production in B cells treated 
with CSB, the differentiation-promoting effect of CSB is not due to, if any, a 
contaminating LPS in the preparation of CSB. In this study, we employed two-step 
cultures of B cells in order to separate the differentiation-inducing effect of CSB from 
its mitogenic effect; without separation of these effects, interpretation of antibody 
production data obtained may be difficult due to the presence of both mitogenic and 
differentiation-inducing effects. B cells were stimulated with CSB in the primary 
culture for 3 days, washed to remove CSB, and recultured at a density of 1 × 105 
cells/well for 4 days to determine the effect of CSB on IgM production. Under these 
conditions, the viable cell number in the CSB-treated cultures did not significantly 
differ from that of the control cultures at the end of the reculture period, and thus the 
differentiation-promoting effect of CSB can be separately evaluated. The concentration 
for the maximal differentiation-inducing effect of CSB determined by this method was 
much less than the concentration required for the maximal mitogenic effect of CSB: the 
stimulatory effect of CSB on IgM production was maximal at 6.3 μg/ml, whereas its 
mitogenic effect was linealy increased up to 100 μg/ml (Fig. 1A and Fig. 2A). Since the 
addition of 6.3 μg/ml of CSB resulted in a 30% increase in the number of valiable cells 
during the primary culture for 3 days (Fig. 1B), overall IgM production in the 
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CSB-treated cultures was calculated to be seven-times greater than the IgM production 
in untreated cultures. Rafi et al. reported that stimulation of B cells with 0.1 and 0.5 
mg/ml of hyaluronic acid resulted in 80% and 120% increases in IgM production, 
respectively [24]. However, in our two-step culture system hyaluronic acid was 
marginally effective but CSB markedly effective at 6.3 μg/ml. Thus CSB is a stronger 
differentiation-promoting agent than hyaluronic acid. Inflammation, infection or injury 
can lead to the release of soluble CSB via degradation of the extracellular matrix, and 
CSB comprises over half of the total soluble glycosaminoglycan content of wound fluid 
[25]. Increased soluble CSB may cause polyclonal activation and proliferation of B 
cells in the earlier phase, and in the later phase, increased B cells may produce a large 
amount of polyclonal antibody even at reduced or null concentrations of CSB.  
Several lines of evidence suggest that CSB is involved in the pathogenesis of 
rheumatoid arthritis, an autoimmune disease of connective tissue. CSB is the dominant 
glycosaminoglycan in proteoglycans secreted by synovial cells [7]. Basic activity of the 
disease and proliferation of the synovial cells correlate with an increased percentage of 
CSB of the total glycosaminoglycan content in the synovium [8]. Furhtermore, 
rheumatoid arthritis chondrocytes are known to synthesize an increased proportion of 
proteoglycans, enriched in CSB [9]. A growing number of pathogens, including viruses, 
parasites and bacteria, have been shown to use cell-surface CS and CSB, in addition to 
heparan sulfate, for their attachment to host cells and tissues [3,10]. In mice, injection 
of glycosaminoglycans such as CSB, CSA, CSC, and hyaluronic acid has been shown to 
induce the onset of arthritis, tendosynovitis and dermatitis [14]. Our data showing 
CSB-induced polyclonal proliferation and differentiation of B cells further support the 
notion that CSB plays a role at sites of inflammation and participates in the regulation 
of autoimmune response. 
Our previous results using specific pharmacological inhibitors of protein kinases 
suggest a role of PKC and PI3K in the proliferation of B cells induced by CSB [15]. 
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Evidence for an essential role of PKC and PI3K in BCR signal transduction has been 
provided by various studies. B cells of mice deficient in PKCβ have been shown to 
exhibit a defective proliferative response to anti-IgM antibody, despite normal T-cell 
activation in response to T cell receptor stimulation [26]. B cells of mice deficient in the 
p85α or p85α-p55α-p50α adaptor proteins of PI3K had diminished proliferative 
responses to both anti-IgM antibody and LPS [27,28], although mice deficient in p110δ 
catalytic subunit had a poor B cell response to anti-IgM antibody but a normal response 
to LPS [29]. IgM production induced by CSB, however, was inhibited by the PKC 
inhibitor but not by the PI3K inhibitor, indicating that the proliferation and 
differentiation of B cells induced by CSB have different susceptibilities to signaling 
protein kinase inhibitors. Two key transcriptional regulators, B lymphocyte-induced 
maturation protein-1 (Blimp-1) and X-box-binding protein-1 (XBP-1), have been 
shown to be necessary for the terminal differentiation of B cells into antibody-secreting 
plasma cells [23]. Little is known about signals that induce Blimp-1 and XBP-1 
although it has been shown that the expression of Blimp-1 is induced by IL-5 [30]. 
Hence it is not known at present whether or not PKC is involved in the regulation of 
expression of the both transcription factors. In contrast to the PKC inhibitor, the MEK 
inhibitor enhanced IgM production promoted by CSB. It has been shown that 
continuous BCR signaling through the Ras-MEK-ERK pathway inhibits LPS-induced 
plasma cell differentiation [31], but neither CSB nor IL-4 increased phosphorylation of 
ERK [15,32]. Thus, the mechanism responsible for augmentation of CSB-induced IgM 
production in B cells treated with the MEK inhibitor remains to be investigated.        
CSB has been shown to interact with CD44, a broadly distributed cell surface 
protein, although the interaction of CD44 with CSB is more modest than that of CD44 
with hyaluronic acid [33]. CD44 is an adhesion molecule with known importance in T 
cell activation, lymphocyte trafficking and tumor cell invasiveness [2,34]. Moreover, 
some studies have suggested that CD44 participates in the activation of monocytes and 
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B cells induced by hyaluronic acid, CSA, CSB or chondroitin sulfate proteoglycans 
[16,24,35]. The involvement of CD44 in the mitogenic and differentiation-inducing 
effects of CSB on murine B cells remains to be determined, although CD44 expression 
in murine B cells increases when B cells are activated with polyclonal stimuli, including 
LPS and interleukin 5 [36], and CD40 ligand-induced B cell proliferation and 
immunoglobulin production are inhibited by immobilized anti-CD44 mAbs [37].  
In conclusion, the results of this study demonstrated that CSB promoted 
polyclonal differentiation of B cells to antibody-secreting cells in the presence of IL-4 
and IL-5 at doses less than those required for the mitogenic effect, and the results 
suggest that PKC but not PI3K is crucial for CSB-induced IgM production. Our data 
further support the notion that CSB plays a role in the regulation of autoimmune 
response. 
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Figure legends 
 
Fig. 1.  CSB-induced proliferation of IL-4- and IL-5-stimulated B cells. (A) Enriched 
B cells were incubated with the indicated doses of CSB or LPS for 45 h in the presence 
of IL-4 and IL-5 and then pulse-labeled with [3H]thymidine for 3 h. The data are 
representative of two independent experiments and expressed as means ± S.E.M. of 
triplicate cultures. (B) Enriched B cells were incubated with the indicated doses of CSB 
or LPS for 3 days in the presence of IL-4 and IL-5. The number of viable cells was 
determined by a Trypan Blue dye-exclusion test. The data are means ± S.E.M. of three 
independent experiments. Values that are significantly different from those of control 
cultures are indicated by *p < 0.05 (Dunnett’s t-test).  
 
Fig. 2.  Enhancement of IgM production in IL-4- and IL-5-stimulated B cells by CSB 
and no inhibitory effect of polymyxin B on CSB-stimulation. Enriched B cells were 
incubated with the indicated doses of CSB or LPS (A, B) or with CSB (6.25 μg/ml) or 
LPS (0.1 μg/ml) (C, D) for 3 days in the presence of IL-4 plus IL-5 and in the presence 
or absence of polymyxin B (PMB, 5 μg/ml) and then washed and recultured for 4 days 
(A, B, D) or for the indicated days (C) in the presence of IL-4 plus IL-5. IgM in the 
culture supernatants was measured by an ELISA (A, C, D). The number of viable cells 
was determined by a Trypan Blue dye-exclusion test (B). The data are means ± S.E.M. 
of three independent experiments. Values that are significantly different from those of 
the respective control cultures are indicated by *p < 0.05, ***p < 0.001 (Dunnett’s 
t-test) (A, C) or (Student’s t-test) (D).  
 
Fig. 3.  Effects of various GAGs on IgM production in IL-4- and IL-5-stimulated B 
cells. Enriched B cells were incubated with the indicated GAGs (6.25 μg/ml), dextran 
sulfate (6.25 μg/ml) or LPS (0.1 μg/ml) for 3 days in the presence of IL-4 and IL-5 and 
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then washed and recultured for 4 days in the presence of IL-4 and IL-5. IgM in the 
culture supernatants was measured by an ELISA. The data are means and S.E.M. of 
three independent experiments. Values that are significantly different from those of 
control cultures are indicated by ***p < 0.001 (Dunnett’s t-test). 
 
Fig. 4.  Increase in the number of IgM-secreting cells in IL-4- and IL-5-stimulated or 
unstimulated cultures by CSB. Enriched B cells were incubated with the indicated doses 
of CSB or LPS for 3 days in the presence (A) and absence (B) of IL-4 and IL-5 and then 
washed and recultured for 2.5 days in the presence (A) and absence (B) of IL-4 and 
IL-5. The number of IgM-secreting cells was measured by an ELISPOT assay. The data 
are means ± S.E.M. of three (A) or four (B) independent experiments. Values that are 
significantly different from those of control cultures are indicated by *p < 0.05, ***p < 
0.001 (Dunnett’s t-test).  
 
Fig. 5.  Increases in CD138-positive cells and CD45R/B220-negative cells in cultures 
incubated with CSB. Enriched B cells were incubated with CSB (6.25 μg/ml) or LPS 
(0.1 μg/ml) for 3 days in the presence of IL-4 and IL-5 and then washed and recultured 
for 2.5 days in the presence of IL-4 and IL-5. The cells were then stained with 
PE-conjugated anti-CD138 mAb and propidum iodide (A and B) or FITC-conjugated 
anti-CD45R/B220 mAb and propidium iodide (C and D) and analyzed by a flow 
cytometer. Histograms (A and C) are representative of three independent experiments. 
The data (B and D) are means and S.E.M. of three independent experiments. The 
percent of CD138-positive cells and CD45R/B220-negative cells were less than 0.15% 
and less than 0.1%, respectively, as stained with isotype control IgGs, PE-conjugated 
rat IgG2a and FITC-conjugated rat IgG2a. *p < 0.05, ***p < 0.001, as compared with 
the values of control cultures (Dunnett’s t-test). 
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Fig. 6.  Effects of the MEK inhibitor PD98059, the PKC inhibitor GF109203X, and 
the PI3K inhibitor wortmannin on IgM production in CSB- and LPS-treated B cells. (A) 
Enriched B cells were treated with or without 12.5 μM PD98059, 1 μM GF109203X or 
100 nM wortmannin for 60 min and then incubated with CSB (1.56 μg/ml) or LPS (0.1 
μg/ml) for 3 days in the presence of IL-4 and IL-5. After washing, the cells were 
recultured for 4 days in the presence of IL-4 and IL-5. (B) Enriched B cells were 
incubated with CSB (1.56 μg/ml) or LPS (0.1 μg/ml) for 3 days in the presence of IL-4 
and IL-5 and then washed and recultured with IL-4 and IL-5 for 4 days in the presence 
of 12.5 μM PD98059, 1 μM GF109203X or 100 nM wortmannin. (C) Enriched B cells 
were treated with or without 12.5 μM PD98059, 1 μM GF109203X or 100 nM 
wortmannin for 60 min and then incubated with CSB (1.56 μg/ml) or LPS (0.1 μg/ml) 
for 3 days in the presence of IL-4 and IL-5. After washing, the cells were recultured 
with IL-4 and IL-5 for 4 days in the presence of the same inhibitor. IgM in the culture 
supernatants was measured by an ELISA. The data are means ± S.E.M. of three 
independent experiments. Values that are significantly different from those of the 
respective control cultures are indicated by *p < 0.05 (Dunnett’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
